🚀 VC round data is live in beta, check it out!
Marksans Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Marksans Pharma and similar public comparables like LB Pharmaceuticals, MannKind, Basilea Pharmaceutica, Bright Minds Biosciences and more.
Marksans Pharma Overview
About Marksans Pharma
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Founded
1992
HQ
Employees
1.3K
Website
Sectors
Financials (LTM)
EV
$836M
Marksans Pharma Financials
Marksans Pharma reported last 12-month revenue of $313M and EBITDA of $61M.
In the same LTM period, Marksans Pharma generated $61M in EBITDA and $43M in net income.
Revenue (LTM)
Marksans Pharma P&L
In the most recent fiscal year, Marksans Pharma reported revenue of $307M and EBITDA of $64M.
Marksans Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $313M | XXX | $307M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $149M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $61M | XXX | $64M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $43M | XXX | $45M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Marksans Pharma Stock Performance
Marksans Pharma has current market cap of $873M, and enterprise value of $836M.
Market Cap Evolution
Marksans Pharma's stock price is $1.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $836M | $873M | -0.2% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMarksans Pharma Valuation Multiples
Marksans Pharma trades at 2.7x EV/Revenue multiple, and 13.6x EV/EBITDA.
EV / Revenue (LTM)
Marksans Pharma Financial Valuation Multiples
As of April 18, 2026, Marksans Pharma has market cap of $873M and EV of $836M.
Equity research analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marksans Pharma has a P/E ratio of 20.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $873M | XXX | $873M | XXX | XXX | XXX |
| EV (current) | $836M | XXX | $836M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 13.6x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 14.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.6x | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 19.5x | XXX | XXX | XXX |
| EV/FCF | 23.2x | XXX | 49.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Marksans Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Marksans Pharma Margins & Growth Rates
Marksans Pharma's revenue in the last 12 month grew by 17%.
Marksans Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Marksans Pharma's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Marksans Pharma's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Marksans Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Marksans Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Marksans Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| LB Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| Basilea Pharmaceutica | XXX | XXX | XXX | XXX | XXX | XXX |
| Bright Minds Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marksans Pharma M&A Activity
Marksans Pharma acquired XXX companies to date.
Last acquisition by Marksans Pharma was on XXXXXXXX, XXXXX. Marksans Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Marksans Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMarksans Pharma Investment Activity
Marksans Pharma invested in XXX companies to date.
Marksans Pharma made its latest investment on XXXXXXXX, XXXXX. Marksans Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Marksans Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Marksans Pharma
| When was Marksans Pharma founded? | Marksans Pharma was founded in 1992. |
| Where is Marksans Pharma headquartered? | Marksans Pharma is headquartered in India. |
| How many employees does Marksans Pharma have? | As of today, Marksans Pharma has over 1K employees. |
| Is Marksans Pharma publicly listed? | Yes, Marksans Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Marksans Pharma? | Marksans Pharma trades under MARKSANS ticker. |
| When did Marksans Pharma go public? | Marksans Pharma went public in 2002. |
| Who are competitors of Marksans Pharma? | Marksans Pharma main competitors are LB Pharmaceuticals, MannKind, Basilea Pharmaceutica, Bright Minds Biosciences. |
| What is the current market cap of Marksans Pharma? | Marksans Pharma's current market cap is $873M. |
| What is the current revenue of Marksans Pharma? | Marksans Pharma's last 12 months revenue is $313M. |
| What is the current revenue growth of Marksans Pharma? | Marksans Pharma revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Marksans Pharma? | Current revenue multiple of Marksans Pharma is 2.7x. |
| Is Marksans Pharma profitable? | Yes, Marksans Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Marksans Pharma? | Marksans Pharma's last 12 months EBITDA is $61M. |
| What is Marksans Pharma's EBITDA margin? | Marksans Pharma's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Marksans Pharma? | Current EBITDA multiple of Marksans Pharma is 13.6x. |
| What is the current FCF of Marksans Pharma? | Marksans Pharma's last 12 months FCF is $36M. |
| What is Marksans Pharma's FCF margin? | Marksans Pharma's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Marksans Pharma? | Current FCF multiple of Marksans Pharma is 23.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.